Seegene Showcases All-in-One Platform for Molecular Diagnostic Testing for Infectious Diseases
|
By LabMedica International staff writers Posted on 25 Apr 2022 |

Seegene, Inc. (Seoul, Korea) showcased its first fully automated MDx system, STARlet-AIOS: All-in-One System at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022).
ECCMID is the world’s premier clinical microbiology & infectious diseases event that brings together experts from many fields to present their latest findings, guidelines and experiences to an audience of over 14,000 colleagues. This year, the congress featured a hybrid format to facilitate an onsite and online experience for attendees allowing for remote and face-to-face opportunities to take part in the multifaceted program. During this event, Seegene showcased AIOS – its first fully automated MDx system. AIOS provides high-throughput real-time PCR workflow starting from nucleic acid extraction, then, real-time PCR, and finally result interpretation. AIOS is a fully automated syndromic MDx system designed in a modular concept while it compiles Seegene’s cutting-edge high multiplex real-time PCR technologies.
A noteworthy feature of AIOS is that its MDx system is composed of independent and detachable modules together with its proprietary SW architecture. Unlike others’ single-body system, AIOS is designed with an extraction/liquid handler and PCR instrument being integrated with an in-house developed robotic arm module. Hospitals and laboratories can either purchase the full package of ‘AIOS’ system or integrate their existing instruments on-site if they already have Seegene’s liquid handler and real-time PCR instrument.
Some of its other highlights include: ‘high-throughput automated syndromic MDx system’. It also adopts a variety of Seegene’s assays that are currently available on the market, which allows for symptom-based tests. And finally, it can identify the exact cause of a specific symptom with a single tube, which will enable both cost- and time- effective tests. The AIOS is ideal for small-to-medium sized hospitals due to its unique modular and assay features.
Related Links:
Seegene, Inc.
Latest ECCMID 2022 News
- BD Presents Latest Automated Solutions to Combat Antimicrobial Resistance at ECCMID 2022
- Boditech Presents Latest IVD Solutions at ECCMID 2022
- CerTest Presents VIASURE Complete Solution for Improved Molecular Diagnostic Workflow
- BioVendor Presents Its Portfolio of IVD Products and Technologies for Lab Automation
- Bio-Rad Exhibits Complete Infectious Disease Testing Portfolio at ECCMID 2022
- Siemens Presents Its Full Portfolio of COVID-19 Testing Solutions at ECCMID 2022
- MeMed Highlights Pioneering Blood Test for Accurately Distinguishing Between Bacterial and Viral Infection
- Abbott Highlights Rapid Diagnostic Platforms to Complement Centralized RT-PCR Testing at ECCMID 2022
- Beckman Coulter Presents Virtual Showcase of MicroScan Microbiology Solutions
- Randox Presents Vivalytic Universal, Fully Automated All-in-One Solution for Molecular Diagnostics at ECCMID 2022
- Meridian Bioscience Exhibits Curian Immunofluorescent Testing Platform at ECCMID 2022
- Copan Showcases Fully Automated Solutions for Antibiotic Susceptibility Testing at ECCMID 2022
- Autobio Diagnostics Showcases Automated Microbial Identification and ID-AST Solutions at ECCMID 2022
- Altona Diagnostics Exhibits AltoStar Product Range at ECCMID 2022
- Alifax Presents First Automated System for Bacterial Culture and Susceptibility Testing at ECCMID 2022
- LumiraDx Demonstrates Use of LumiraDx Platform in Infectious Disease Testing at ECCMID 2022
Channels
Clinical Chemistry
view channel
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read moreMolecular Diagnostics
view channel
Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more
Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence
SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more
Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests
Cancer screening is intended to reduce mortality, but policy decisions often depend on early indicators that may not fully reflect true survival benefit. The emergence of blood-based tests capable of detecting... Read moreHematology
view channel
Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
Iron deficiency in school-age children can affect brain development, learning, growth, and physical performance, yet early deficiency may be missed when screening focuses mainly on anemia.... Read more
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read moreImmunology
view channel
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read more
Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
Lung transplant recipients face some of the highest rates of acute cellular rejection, and routine surveillance often relies on repeated surgical biopsies. These procedures can cause complications such... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read moreTechnology
view channel
Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. Safety‑net primary care settings often face barriers that limit screening... Read more
Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
Chronic liver disease is common and often progresses silently, increasing the risk of cirrhosis and hepatocellular carcinoma when not detected early. With an estimated 1.5 billion people affected worldwide... Read moreIndustry
view channelWerfen and Oxford Nanopore Collaborate on Transplant Assay Development
Werfen (Barcelona, Spain), a global specialized diagnostics company, has announced a strategic collaboration with Oxford Nanopore Technologies (Oxford, UK), which develops nanopore-based sequencing technology,... Read more









